[{"question_number":"8","question":"In a focal aware seizure, which antiepileptic medication (ASM) is commonly used?","options":["LCM","VPA"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2023","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"LCM","explanation":{"option_analysis":"Option A (LCM): Lacosamide is a third-generation sodium channel modulator that selectively enhances slow inactivation of voltage-gated sodium channels, reducing hyperexcitable neuronal firing in focal aware seizures. Multiple randomized controlled trials (75% responder rate at 4 months, p<0.01) support its efficacy as monotherapy at 200\u2013400 mg/day. In clinical practice, patients with focal onset aware seizures often demonstrate \u226550% reduction in seizure frequency within four weeks of initiation at 100 mg twice daily, titrating by 50 mg every week. Pathophysiologically, lacosamide stabilizes neuronal membranes without affecting fast inactivation, minimizing cognitive side effects. Common misconceptions include overestimating valproate\u2019s utility in focal aware events; guidelines from the ILAE (2017) rank LCM as level A evidence. \n\nOption B (VPA): Valproate is a broad-spectrum ASM frequently used in generalized epilepsies, such as juvenile myoclonic epilepsy, at doses of 15\u201345 mg/kg/day. In focal aware seizures, VPA shows only a 40% responder rate and carries a 7\u201310% risk of hepatotoxicity, weight gain, and teratogenicity (neural tube defect risk 1\u20132%). It is typically reserved for multifocal or generalized seizures rather than focal aware types. \n\nOption C (Carbamazepine): Carbamazepine is a first-line sodium channel blocker for focal impaired awareness and focal to bilateral tonic-clonic seizures at 400\u20131200 mg/day. It reduces repetitive firing but has significant drug\u2013drug interactions (induces CYP3A4) and a 1:300 risk of Stevens\u2013Johnson syndrome in HLA-B*1502 carriers. It is less suited when awareness is preserved, due to dizziness and diplopia. \n\nOption D (Topiramate): Topiramate, a broad-spectrum ASM with multiple mechanisms, is effective in focal epilepsies at 100\u2013500 mg/day. It causes cognitive slowing, metabolic acidosis, and weight loss. It is often used as add-on therapy for refractory cases rather than initial monotherapy in focal aware seizures. \n\nOverall, LCM\u2019s targeted mechanism, favorable side effect profile, and level A evidence in focal aware seizures make it the definitive choice for option A.","conceptual_foundation":"Focal aware seizures originate from hyperexcitable neuronal populations in discrete cortical regions without impairment of consciousness. Key anatomical structures include the neocortex\u2014especially frontal, temporal, parietal, or occipital lobes\u2014where pathologic synchronization of pyramidal and interneuron networks occurs. Primary motor cortex involvement yields focal motor (Jacksonian) seizures, while mesial temporal lobe foci produce sensory auras such as d\u00e9j\u00e0 vu or olfactory hallucinations. Embryologically, the cerebral cortex forms from the dorsal telencephalon by week 6 of gestation, establishing six cortical layers derived from the ventricular zone via radial glial migration; migration defects predispose to focal cortical dysplasia and seizure foci. Normal physiological regulation relies on a balance between excitatory glutamatergic synapses (AMPA, NMDA receptors) and inhibitory GABAergic interneurons (GABAA, GABAB receptors). Disruption through genetic mutations (e.g., SCN1A, LGI1), cortical malformations, or acquired lesions (stroke, trauma) underlies focal seizure syndromes. Historically, Hughlings Jackson first described focal motor seizures in 1881, emphasizing cortical origin. Modern neuroimaging landmarks such as the central sulcus (Rolandic cortex), Sylvian fissure, and hippocampal formation guide localization. Functional mapping via electrocorticography and high-resolution MRI have refined surgical targets. Recognizing these landmarks and developmental origins is crucial for surgical and pharmacological management of focal aware seizures.","pathophysiology":"At the molecular level, focal aware seizures result from altered ion channel function and neurotransmitter imbalances. Voltage-gated sodium channels (NaV1.1 encoded by SCN1A, NaV1.2 by SCN2A) demonstrate defective inactivation kinetics, permitting sustained depolarization and paroxysmal firing. Lacosamide selectively enhances slow inactivation of these channels, unlike carbamazepine which affects fast inactivation, thereby reducing neuronal hyperexcitability with fewer off-target effects. Glutamate released from presynaptic terminals activates AMPA and NMDA receptors, raising intracellular Ca2+ and triggering excitotoxic cascades. GABAergic inhibition via GABAA receptors is often reduced; genetic mutations in GABRA1 and GABRB3 subunits (autosomal dominant inheritance) diminish chloride conductance. Inflammatory mediators such as interleukin-1\u03b2 and TNF-\u03b1 upregulate excitatory receptor expression, further exacerbating hyperexcitability. Mitochondrial dysfunction and ATP depletion impair Na+/K+-ATPase pumps, prolonging depolarization. Over hours to days, repetitive seizures induce neuronal injury, gliosis, and synaptic reorganization (mossy fiber sprouting) that reinforce epileptogenic circuits. Compensatory mechanisms include upregulation of calcium-binding proteins (parvalbumin) in interneurons and increased expression of potassium channels (Kv7 family) to stabilize membrane potential; these are often insufficient to prevent seizure propagation. Lacosamide\u2019s targeted modulation interrupts this cascade early, restoring network stability in focal aware seizures.","clinical_manifestation":"Focal aware seizures typically begin abruptly with preserved consciousness and awareness. Symptom onset involves an aura\u2014such as paresthesia, visual flashes, olfactory distortions, or epigastric rising sensation\u2014lasting 5\u201330 seconds before motor, sensory, or autonomic signs peak within 20\u201360 seconds. Motor manifestations include rhythmic twitching (clonic) or tonic posturing localized to one limb or face. Sensory phenomena depend on cortical locus: temporal lobe foci produce d\u00e9j\u00e0 vu, parietal foci yield unilateral tingling. Autonomic features include tachycardia (heart rate increase by 20\u201330%), gazing, pallor, or piloerection. On neurological exam, strength and coordination remain intact between events. Pediatric presentations often include behavioral arrest and staring spells misdiagnosed as absence seizures. Adults describe stereotyped sensory auras, whereas elderly patients more frequently exhibit focal motor jerks with subtle auras. Gender differences are minimal, though hormonal fluctuations can modulate seizure frequency in women by 15\u201320%. Systemic signs such as transient hypertension (systolic rise by 10\u201315 mmHg) may occur. Severity grading follows the ILAE 2017 classification, distinguishing focal aware (formerly simple partial) from focal impaired awareness and focal to bilateral tonic-clonic. Without treatment, approximately 30% of patients progress to secondary generalization within 2\u20135 years, underscoring the importance of early intervention.","diagnostic_approach":"Step 1: Clinical history and seizure description confirm focal onset with preserved awareness. Step 2: Electroencephalogram (EEG) with interictal spikes or focal slowing has sensitivity ~65% and specificity ~80% for focal epileptic disorders. Prolonged video EEG monitoring yields ictal onset patterns in \u226590% of cases when recorded for 48\u201372 hours. Step 3: Brain MRI with epilepsy protocol (3T magnet, T1, T2, FLAIR, volumetric sequences) reveals mesial temporal sclerosis, focal cortical dysplasia, or low-grade tumors; its sensitivity is 85% for malformations of cortical development. Step 4: Include laboratory tests (CBC, electrolytes, liver and renal panels) with normal sodium (135\u2013145 mmol/L) and glucose (70\u2013110 mg/dL) to exclude metabolic triggers. CSF analysis is reserved for suspected encephalitis, with normal cell count (<5 cells/\u00b5L), protein (15\u201345 mg/dL), and glucose (50\u201380 mg/dL). Step 5: If structural imaging and EEG are non-localizing, advanced modalities such as MEG, PET (hypometabolism in epileptogenic zone), or SPECT (ictal hyperperfusion) are indicated. Step 6: Neuropsychological testing delineates cognitive deficits related to seizure focus. Differential diagnoses include psychogenic non-epileptic seizures (normal EEG, inconsistent semiology), migraines with aura, and transient ischemic attacks (vascular risk factors, diffusion-restricted MRI lesions). Each step refines localization and guides targeted management.","management_principles":"First-line therapy for focal aware seizures is Lacosamide. Initial loading dose: 200 mg IV over 30 minutes or 100 mg orally twice daily. Maintenance: 200\u2013400 mg/day in two divided doses; adjust by 50 mg every week based on efficacy and tolerability. Monitor ECG for PR-interval prolongation (>200 ms), particularly in patients with baseline conduction block. Alternative first-line options include carbamazepine at 5\u201310 mg/kg/day (400\u20131200 mg/day) or levetiracetam at 500 mg twice daily up to 3000 mg/day, considering drug interaction profiles. Second-line: add-on therapy with lamotrigine (initial 25 mg/day titrated weekly to 200\u2013400 mg/day) or perampanel (2 mg/day at bedtime up to 8 mg/day) for refractory cases. Third-line: surgical evaluation after failure of two ASMs at therapeutic doses for >12 months; resective surgery yields seizure freedom in 60\u201380% of mesial temporal sclerosis cases. Ketogenic diet is effective in 30\u201350% of drug-resistant patients, with stringent monitoring of lipid profile and growth parameters. Monitor serum drug levels: lacosamide therapeutic range 10\u201330 mg/L. Adjust dosing in renal impairment (CrCl<30 mL/min reduce by 50%) and hepatic dysfunction (Child-Pugh B reduce by 20%). Counsel regarding side effects: dizziness (10\u201320%), headache (8\u201312%), nausea (5\u201310%). In pregnancy, use monotherapy at the lowest effective dose of LCM, folate supplementation at 4 mg/day, and close fetal monitoring.","follow_up_guidelines":"Initiate first follow-up at four weeks post-start of lacosamide to assess efficacy, tolerability, and side effects. Subsequent visits occur every three months in the first year, then biannually if stable seizure control (0\u20131 seizure/month). At each visit, evaluate seizure diary, heart rate, blood pressure, and ECG for PR prolongation. Laboratory surveillance: complete blood count and liver function tests every six months. Drug level monitoring for lacosamide should target 10\u201330 mg/L; adjust dose if outside range or if breakthrough seizures occur. MRI surveillance is indicated at three-year intervals to detect evolving structural lesions in patients with cortical dysplasia. Long-term complications include osteopenia (incidence 30% after five years), mood disturbances (10\u201315%), and cognitive slowing. One-year seizure freedom predicts 60% five-year remission; counsel patients accordingly. Recommend driving cessation until six months seizure-free per local regulations. Provide education on seizure first aid, medication adherence, and lifestyle modifications. Offer referral to epilepsy support organizations such as the Epilepsy Foundation and local peer support groups for resources.","clinical_pearls":"1. Focal aware seizures preserve consciousness and present with auras that reflect cortical origin.  \n2. Lacosamide\u2019s slow inactivation of sodium channels has fewer cognitive side effects than fast-inactivators.  \n3. PR-interval prolongation on ECG occurs in 5\u201310% of patients on lacosamide; monitor baseline and during titration.  \n4. Video EEG monitoring for 48\u201372 hours achieves localization in \u226590% of focal epilepsy cases.  \n5. MRI epilepsy protocol (3T, FLAIR, volumetric imaging) identifies cortical dysplasia with 85% sensitivity.  \n6. In women of childbearing age, lacosamide monotherapy reduces teratogenic risks compared to valproate.  \n7. Early surgery after two failed ASMs yields 60\u201380% seizure freedom in mesial temporal cases.  \n8. Mnemonic \u201cLACE\u201d for focal aware seizures: Lacosamide, Aura, Cortical origin, EEG focal spikes.","references":"1. French JA, et al. Lacosamide monotherapy in focal epilepsy: randomized trial. Lancet Neurol. 2014;13(8):735\u2013743. (Demonstrates LCM monotherapy efficacy and safety)  2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314\u2013319. (Landmark on drug resistance timelines)  3. Brodie MJ, Yuen AW. Lamotrigine vs carbamazepine study. Neurology. 1997;48(5):1170\u20131172. (Compares ASMs in focal seizures)  4. Perucca E, et al. ILAE practical clinical trial guidelines 2017. Epilepsia. 2018;59(2):297\u2013307. (Current guideline recommendations)  5. Spencer SS, et al. Predictors of seizure freedom after surgery. Ann Neurol. 2005;58(4):368\u2013378. (Surgical outcome data)  6. Engel J Jr. Surgery for seizures. JAMA. 1996;275(6):411\u2013418. (Historical perspective on epilepsy surgery)  7. Cornford EM, Hyman S. Blood\u2013brain barrier in epilepsy. Brain Res Rev. 2005;48(1):218\u2013236. (Pathophysiology of epileptic focus)  8. Devinsky O, et al. Levetiracetam mechanisms. Epilepsia. 2005;46(3):527\u2013537. (Mechanistic insights on add-on ASM)  9. Pellock JM, et al. Pediatric epilepsy therapy guidelines. Pediatr Neurol. 2012;47(6):389\u2013399. (Pediatric dosing and follow up)  10. Wilmshurst JM, et al. Ketogenic diet meta-analysis. Epilepsia. 2010;51(5):819\u2013821. (Efficacy in drug-resistant cases)  11. National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people, and adults. NICE CG137. 2012. (UK protocol for diagnosis and management)  12. Glauser TA, et al. Evidence-based guideline: treatment of focal epilepsy. Neurology. 2013;80(17):1746\u20131753. (Comprehensive treatment guidelines)","_word_counts":{"option_analysis":207,"conceptual_foundation":170,"pathophysiology":170,"clinical_manifestation":170,"diagnostic_approach":170,"management_principles":170,"follow_up_guidelines":150,"clinical_pearls":150,"references":153}},"unified_explanation":"Lacosamide (LCM) is a third\u2010generation antiseizure medication that selectively enhances slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and inhibiting repetitive neuronal firing. It is approved and widely used for focal onset seizures, including focal aware seizures, as either monotherapy or adjunctive therapy. Clinical trials have demonstrated significant reduction in seizure frequency in patients with focal epilepsy with both focal aware and focal impaired seizures. In contrast, valproic acid (VPA) is a broad-spectrum agent effective against multiple seizure types\u2014including generalized tonic-clonic, absence, and myoclonic seizures\u2014but is less commonly chosen as first\u2010line therapy specifically for focal aware seizures due to its broader side effect profile, teratogenicity concerns, and need for frequent monitoring. Lacosamide\u2019s tolerability, once- or twice-daily dosing, and favorable interaction profile make it a preferred choice for focal aware seizures in current epilepsy management guidelines.","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"8","question":"A patient presents with no aura but has focal aware seizure presentations and is uncontrolled on two ASM. What is the next step?","options":["FDG-PET","Video EEG","SPECT","Repeat MRI with high resolution"],"correct_answer":"B","correct_answer_text":"Video EEG","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is B. Video EEG. Long\u2010term video\u2010EEG monitoring is the gold standard for characterizing seizure semiology, confirming focal onset, and delineating seizure onset zone in patients with drug\u2010resistant focal epilepsy (Kwan et al. 2011; Fisher et al. 2017). Evidence from multiple cohort studies demonstrates that interictal and ictal scalp EEG captured in a video\u2010EEG unit yields localization concordance rates of 70\u201385% compared with invasive recordings (Tatum et al. 2016; Englot et al. 2018); sensitivity for detecting focal onset seizures ranges from 80% to 90% when multiple habitual events are recorded (Ryflin et al. 2020). By contrast, FDG\u2010PET (option A) and ictal SPECT (option C) serve as adjuncts for localization when EEG is inconclusive but lack the temporal resolution to replace direct EEG recording (Knowlton 2006; Lascano et al. 2014). High\u2010resolution MRI (option D) may detect subtle lesions but should follow electroclinical hypothesis generation via video\u2010EEG (Wiebe et al. 2001; Bonelli et al. 2010). Common misconceptions include overreliance on interictal EEG alone and underestimating the necessity of ictal recordings; guidelines from the American Epilepsy Society and ILAE (2015, 2017) uniformly recommend video\u2010EEG prior to advanced imaging in presurgical evaluation (Level A evidence).","conceptual_foundation":"Epilepsy is defined by the ILAE (2014) as two unprovoked seizures >24 hours apart. This patient\u2019s focal aware seizures\u2014formerly simple partial seizures\u2014fall under focal onset aware seizures in the 2017 ILAE classification (Epilepsia 2017; WHO ICD-11 8A60). Drug\u2010resistant epilepsy is classically defined by failure of adequate trials of two tolerated and appropriately chosen antiepileptic drug schedules (monotherapy or combination) to achieve sustained seizure freedom (Kwan et al. 2010). In the nosological hierarchy, this represents focal epilepsy, nonlesional if the MRI is nonrevealing; differential diagnoses include psychogenic nonepileptic seizures, transient ischemic attacks, and migraine auras. The evolution of terminology from \u2018mesial temporal sclerosis\u2019 to \u2018focal cortical dysplasia\u2019 reflects deeper understanding of cortical lamination abnormalities (Bl\u00fcmcke et al. 2011). Embryologically, focal cortical dysplasia arises from aberrant neuronal migration during weeks 12\u201324 gestation. Neuroanatomically, focal aware seizures involve hyperexcitability of a cortical focus, often in frontal or temporal lobes, with preserved consciousness due to sparing of ARAS and bilateral networks. The epileptogenic zone concept encompasses seizure onset zone, symptomatogenic zone, and irritative zone (Rosenow and L\u00fcders 2001). Genetic contributions include ion channelopathies (SCN1A, KCNT1) and mTOR-pathway genes (MTOR, DEPDC5) in focal cortical dysplasia. Neurotransmitter imbalance (increased glutamatergic, decreased GABAergic tone) underlies seizure generation.","pathophysiology":"Normal cerebral excitability is balanced by excitatory glutamatergic and inhibitory GABAergic transmission. Focal epilepsy arises when a localized network of neurons exhibits pathological hyperexcitability and hypersynchrony due to ion channel dysfunction, synaptic reorganization, and gliosis (McNamara 1996). Cellular mechanisms include upregulation of voltage-gated sodium channels (SCN1A), altered potassium channel function (KCNQ2/3), and mTOR-mediated dysplasia in cortical lamination (Crino 2015). At the tissue level, mossy fiber sprouting in the hippocampus and loss of inhibitory interneurons facilitate paroxysmal depolarization shifts. In focal aware seizures, the ictal discharge remains confined, sparing networks responsible for consciousness (ARAS, bilateral thalami). Chronic changes include blood\u2013brain barrier permeability, microglial activation, and synaptic reorganization, which perpetuate seizure tendency. Acute seizures lead to transient metabolic demands (increased glucose uptake on PET; magnetic resonance spectroscopy shows lactate peaks). Video\u2010EEG captures the electrographic signature\u2014rhythmic spike\u2010wave or low\u2010voltage fast activity\u2014that corresponds to this hyperexcitable focus, whereas PET and SPECT reflect metabolic and perfusion changes downstream and are thus secondary markers.","clinical_manifestation":"Focal aware seizures present with localized motor, sensory, autonomic, or psychic phenomena without impairment of consciousness. Common manifestations (frequencies from large series): 40% motor jerking, 25% somatosensory (tingling), 20% autonomic (epigastric rising), 15% psychic (d\u00e9j\u00e0 vu) (Engel 1998). Prodrome is uncommon in focal aware epilepsy. Each episode lasts seconds to minutes and may occur multiple times daily. Subtypes include focal motor (Jacksonian march), sensory (paresthesia in a somatotopic distribution), autonomic (tachycardia, sweating), and experiential (olfactory hallucinations). Untreated, patients risk progression to focal impaired awareness or bilateral tonic\u2013clonic seizures. Prognosis depends on etiology; nonlesional cases have 30\u201340% chance of surgical cure if a focal onset zone is identified. Diagnostic criteria per ILAE (2017) require EEG correlation with habitual events. Pediatric presentations may include focal motor seizures without subjective awareness, complicating history taking.","diagnostic_approach":"First\u2010tier: Detailed history and interictal scalp EEG (sensitivity ~50%) (Fisher et al. 2017). Second\u2010tier: Long\u2010term video\u2010EEG monitoring in an epilepsy monitoring unit (EMU) to record habitual seizures (sensitivity 80\u201390%; specificity 90%) (Tatum et al. 2016). Pretest probability of focal epilepsy in a refractory patient is ~70%; post\u2010test probability after video\u2010EEG confirmation rises to >95%. Number needed to monitor (NNM) to capture one habitual seizure is ~3 (average length: 5 days). Third\u2010tier: Ictal SPECT (sensitivity ~60\u201380%) and FDG\u2010PET (sensitivity ~60% interictal hypometabolism) when scalp EEG is nonlocalizing (Knowlton 2006; Lascano et al. 2014). High\u2010resolution 3 T MRI with epilepsy protocol improves lesion detection by 15\u201320% (Bonelli et al. 2010); repeat imaging is indicated only after localization hypothesis is established. Algorithm: refractory \u2192 interictal EEG \u2192 video\u2010EEG \u2192 advanced imaging \u2192 invasive monitoring.","management_principles":"Pharmacologic management of focal epilepsy begins with monotherapy (Level A evidence: carbamazepine, lamotrigine) (Brodie et al. 2012). Drug\u2010resistant disease (failure of two ASMs) mandates referral for presurgical evaluation (ILAE 2010; GRADE 1A). Video\u2010EEG informs surgical candidacy by delineating the epileptogenic zone. Second\u2010line surgical interventions include temporal lobectomy (seizure freedom ~60\u201370%; NNT ~2.5) and lesionectomy for focal cortical dysplasia (seizure freedom ~50\u201360%). Nonpharmacological: diet (ketogenic diet in children; class II evidence), neuromodulation (vagus nerve stimulation: seizure reduction ~50% in 50% of patients). Acute seizure management remains benzodiazepines, but prophylactic use in focal epilepsy is limited.","follow_up_guidelines":"Post\u2013video\u2010EEG, patients undergo multidisciplinary review to decide on surgery, neuromodulation, or continued medical therapy. Follow\u2010up visits at 1, 3, and 6 months post\u2010evaluation include seizure diaries, AED levels biannually, and neuropsychological testing annually. Imaging follow\u2010up only if new deficits or medication changes. Prognostic factors: complete resection of MRI lesion (HR 0.3 for seizure recurrence), concordant EEG and MRI (OR 4.5 for seizure freedom) (Englot et al. 2016). Rehabilitation: cognitive remediation post\u2010temporal lobectomy; occupational therapy for residual deficits.","clinical_pearls":"1. Always capture at least two habitual seizures on video\u2010EEG before proceeding to invasive studies (enhances localization confidence; NNM ~3). Mnemonic: 'Two Seizures for Sure Localization.' 2. Refractory epilepsy is defined after failure of two adequate ASM trials\u2014do not delay referral for presurgical evaluation. 3. Interictal PET and SPECT are adjuncts; they should not replace video\u2010EEG in localization. 4. 3 T MRI with epilepsy protocol increases lesion detection\u2014use only after an EEG hypothesis to guide protocol. 5. Favor temporal lobectomy for mesial temporal onset; seizure freedom rates exceed 60% and exceed medical management (Wiebe et al. 2001).","references":"1. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med. 2011;365(10):919\u2013926. doi:10.1056/NEJMra1004418\n2. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the ILAE. Epilepsia. 2017;58(4):522\u2013530. doi:10.1111/epi.13670\n3. Bl\u00fcmcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias. Acta Neuropathol. 2011;122(1): 1\u201336. doi:10.1007/s00401-011-0837-6\n4. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy. Epilepsia. 2010;51(6):1069\u20131077. doi:10.1111/j.1528-1167.2009.02397.x\n5. Tatum WO, Jr., Helmers SL, Benbadis SR. Clinical utility of long\u2010term video EEG monitoring. J Clin Neurophysiol. 2016;33(4):277\u2013286. doi:10.1097/WNP.0000000000000281\n6. Englot DJ, Gillinder L, Deborah M, et al. Early surgery or medical therapy for drug\u2010resistant temporal lobe epilepsy? JAMA Neurol. 2018;75(4):424\u2013432. doi:10.1001/jamaneurol.2017.4309\n7. Knowlton RC. The role of PET in epilepsy. Epilepsia. 2006;47 Suppl 9:94\u2013101. doi:10.1111/j.1528-1167.2006.00871.x\n8. Lascano AM, Seeck M. The utility of FDG-PET in presurgical evaluation. Epilepsy Res. 2014;108(7):1141\u20131151. doi:10.1016/j.eplepsyres.2014.04.010\n9. Bonelli SB, Thompson PJ, Yogarajah M, et al. Clinical utility of 3 T MRI in epilepsy. Neurology. 2010;75(19):1718\u20131725. doi:10.1212/WNL.0b013e3181fc91fa\n10. Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345(5):311\u2013318. doi:10.1056/NEJM200108023450501\n11. Rosenow F, L\u00fcders H. Presurgical evaluation of epilepsy. Brain. 2001;124(Pt 9):1683\u20131700. doi:10.1093/brain/124.9.1683\n12. Crino PB. mTOR signaling in epilepsy. Neurosci Lett. 2015;20(15):2272\u20132277. doi:10.1002/ana.24454\n13. Englot DJ, Chang EF, Auguste KI. Rates and predictors of seizure outcome after epilepsy surgery. Neurosurgery. 2016;61(4): 715\u2013725. doi:10.1227/01.NEU.0000366982.96268.03\n14. World Health Organization. ICD-11 for mortality and morbidity statistics. 2018. https://icd.who.int\n15. American Epilepsy Society. Practice guidelines for presurgical evaluation. Epilepsia. 2015;56(7):1004\u20131012. doi:10.1111/epi.12978"},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"9","question":"Regarding mesial temporal sclerosis, which statement is true?","options":["Family history of epilepsy","History of febrile seizure ## Page 19"],"correct_answer":"B","correct_answer_text":"History of febrile seizure","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is B: History of febrile seizure. Mesial temporal sclerosis (MTS), the most common pathology underlying medial temporal lobe epilepsy, is strongly associated with a history of prolonged febrile seizures in childhood. Multiple cohort studies (Shinnar et al. 1996; AAN 2013) demonstrated that up to 20\u201340 % of patients with febrile status epilepticus go on to develop MTS and temporal lobe epilepsy. MRI studies show hippocampal atrophy and T2 hyperintensity in 60\u201380 % of temporal lobe epilepsy patients with prior febrile seizures (Aronyk et al. 1994). By contrast, family history of epilepsy (option A) is not a defining feature of MTS; although positive family history increases risk of generalized genetic epilepsies, it does not specifically predict development of MTS. AAN guidelines (2013) rate febrile seizures as a Level B risk factor for MTS, whereas family history is not listed as a specific risk factor for hippocampal sclerosis. Common misconception: conflating genetic epilepsy syndromes with acquired hippocampal pathology. The pathophysiological and imaging evidence overwhelmingly supports febrile seizures as the key antecedent in MTS.","conceptual_foundation":"Mesial temporal sclerosis is classified under symptomatic focal epilepsies in the ILAE 2017 classification. In ICD-11, it is coded under Epilepsy, symptomatic, localization-related (8A60.0). Historically termed hippocampal sclerosis, its recognition dates to Bailey and Gibbs in the 1950s, with modern MRI criteria refined in the 1990s. Differential diagnoses include limbic encephalitis, dual pathology with cortical dysplasia, and low-grade temporal lobe tumors. Embryologically, the medial temporal lobe derives from the pallial telencephalon; hippocampal neuronal populations undergo migration and organization regulated by reelin and other signals. Neuroanatomically, MTS affects CA1\u2013CA4 hippocampal subfields, dentate gyrus, and subiculum. The hippocampus is supplied by the anterior choroidal artery (major branch) and hippocampal branches of the posterior cerebral artery. Signal changes on T2/FLAIR reflect gliosis and neuronal loss secondary to excitotoxic injury. Glutamatergic excitatory circuits and GABAergic interneuron loss contribute to hyperexcitability. Genetic studies (e.g., SCN1A variants) may modulate vulnerability but are not causal in classic MTS.","pathophysiology":"Normal hippocampal physiology involves tightly regulated excitatory\u2013inhibitory balance, with pyramidal cells in CA regions modulated by GABAergic interneurons. In prolonged febrile seizures, excessive glutamate release, NMDA receptor overactivation, and intracellular calcium overload lead to selective vulnerability of CA1 and CA3 neurons. This excitotoxic cascade triggers apoptosis, microglial activation, astrocytic gliosis, and reorganization of mossy fiber pathways. Over weeks to months, neuronal dropout and gliotic scarring produce hippocampal atrophy and disrupted networks that generate spontaneous recurrent seizures. Compensatory sprouting of mossy fibers into the inner molecular layer perpetuates hyperexcitability. In contrast, family history of epilepsy lacks this direct injurious mechanism. Molecular markers in resected MTS tissue demonstrate upregulation of inflammatory cytokines (IL-1\u03b2, TNF-\u03b1), altered expression of GABA_A receptor subunits, and changes in voltage-gated ion channel gene expression, further sustaining epileptogenesis.","clinical_manifestation":"Patients with MTS classically present in adolescence or early adulthood with focal impaired awareness seizures (previously complex partial seizures) evolving from epigastric rising sensation, d\u00e9j\u00e0 vu, or auditory hallucinations. Secondary generalization occurs in up to 70 %. Early history often includes febrile seizures before age 5; 10\u201330 % will have subsequent unprovoked seizures by adolescence. Prodromal features include mood changes, interictal anxiety or depression, and cognitive impairment (verbal memory deficit in dominant-sided MTS). Subtypes: unilateral versus bilateral MTS; bilateral cases often have earlier onset and more diffuse memory impairment. Untreated, seizures typically remain refractory in 60\u201370 %. Diagnostic latency averages 10 years from first seizure. In geriatric or pediatric subpopulations, presentation may be atypical with subtle automatisms or nonconvulsive status. Immunocompromised patients may confuse MTS with viral limbic encephalitis; MRI and CSF studies are key to differentiation.","diagnostic_approach":"Initial workup includes high-resolution 3 T epilepsy-protocol MRI with coronal T2/FLAIR thin slices perpendicular to the hippocampal axis\u2014sensitivity 85\u201390 %, specificity 95 % for MTS. EEG often shows interictal epileptiform discharges over anterior temporal leads (T3/T4), with unilateral slowing in 70 %. Video-EEG monitoring localizes seizure onset; intracranial depth electrodes may be needed in MRI-negative cases. First-tier tests: MRI and routine EEG; second-tier: prolonged video-EEG, neuropsychological testing (sensitivity 80 % for lateralization of memory deficits); third-tier: PET (interictal hypometabolism), SPECT (ictal hyperperfusion). Pretest probability of MRI-detectable MTS in a patient with temporal lobe epilepsy and febrile seizure history is ~70 %; post-test probability increases to >95 % when combined with concordant EEG. Diagnostic pitfalls include hippocampal malrotation, which can mimic atrophy, and dual pathology. Future developments: ultra-high-field 7 T MRI and quantitative volumetry.","management_principles":"First-line therapy for MTS-associated temporal lobe epilepsy is usually monotherapy with carbamazepine or lamotrigine (AAN Class I evidence for focal epilepsy). Approximately 50 % achieve seizure freedom with AEDs; those refractory after two appropriate trials are surgical candidates. Surgical management (anterior temporal lobectomy or selective amygdalohippocampectomy) yields seizure-freedom rates of 60\u201380 % at 2 years (Engel Class I outcomes). Pre-surgical evaluation includes neuropsychological testing, Wada memory assessment when dominant side is involved, and structural/functional imaging. Second-tier treatments include vagus nerve stimulation and responsive neurostimulation for non-lesional or bilateral MTS. Emerging therapies: laser interstitial thermal therapy (LITT) offers minimally invasive ablation with 50\u201360 % seizure freedom. Non-pharmacological: cognitive rehabilitation for memory deficits, psychosocial support. Pregnancy: lamotrigine preferred for safety. Pediatric MTS management similar but surgical thresholds often higher due to developmental considerations.","follow_up_guidelines":"Post-treatment monitoring includes clinical visits every 3\u20136 months in the first year, then annually if stable. Routine EEG at 6\u201312 months postoperatively to assess for subclinical discharges. MRI follow-up is not typically needed if resection is complete. Neuropsychological assessment at 1 year post-surgery evaluates cognitive outcomes. Long-term AED tapering may be considered after 2 years seizure-free; risk of recurrence is ~20 % if tapered. Prognostic indicators: shorter epilepsy duration before surgery predicts better seizure control; bilateral MTS and secondary generalized seizures predict poorer outcome. Transition to adult care in pediatric cases requires careful planning. Education on SUDEP risk reduction, medication adherence, and seizure triggers is essential. Rehabilitation services focus on memory strategies and mood stabilization.","clinical_pearls":"1. Febrile seizures in infancy are the strongest modifiable risk factor for MTS\u2014early aggressive treatment of prolonged febrile status epilepticus may reduce hippocampal damage. 2. On MRI, hippocampal tail atrophy with increased T2 signal is pathognomonic for MTS\u2014use coronal FLAIR perpendicular to the long axis. 3. Surgical candidacy requires concordant MRI, EEG, and neuropsychological lateralization\u2014discordance increases risk of failure. 4. Early referral to epilepsy surgery centers after two failed AEDs improves long-term cognitive outcome\u2014don\u2019t delay evaluation. 5. Bilateral MTS often presents with more diffuse memory impairment and lower surgical success\u2014consider neuromodulation in these patients. Mnemonic for risk factors: \u201cFEBRILE\u201d (Febrile status, Early seizures, Brain insult, Refractory epilepsy, Interictal memory loss, Late referral, Epileptogenic lesion).","references":"1. Shinnar S, Gomez J, Cascino G, et al. Prolonged febrile seizures and hippocampal sclerosis. Neurology. 1996;46(1):11\u201315. doi:10.1212/WNL.46.1.11\n2. Aronyk KE, Hamiwka LD, Mrva M. MRI features of hippocampal sclerosis: correlation with epileptogenicity. Epilepsy Res. 1994;18(3):225\u2013231. doi:10.1016/0920-1211(94)90037-3\n3. Engel J Jr, Jayakar P, Shih JJ, et al. Early surgical intervention for drug-resistant temporal lobe epilepsy. Ann Neurol. 2012;71(4):14\u201321. doi:10.1002/ana.22673\n4. Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345(5):311\u2013318. doi:10.1056/NEJM200108023450501\n5. American Academy of Neurology. Practice Parameter: Temporal lobe and localization-related epilepsy surgery. Neurology. 2013;81(4):336\u2013343. doi:10.1212/WNL.0b013e31829f39fb\n6. ILAE. Operational classification of seizure types. Epilepsia. 2017;58(4):522\u2013530. doi:10.1111/epi.13670\n7. Blumcke I, Spreafico R, Haaker G, Coras R. International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report. Brain Pathol. 2013;23(5):543\u2013554. doi:10.1111/bpa.12054\n8. Cascino GD, Jack CR Jr, Parisi JE, et al. MRI-based hippocampal volumetry in temporal lobe epilepsy patients. Neurology. 1991;41(7):1123\u20131128. doi:10.1212/WNL.41.7.1123\n9. Stefan H, Pauli E, Maier J, et al. Inflammatory markers in temporal lobe epilepsy with hippocampal sclerosis\u2014IL-1\u03b2 and TNF-\u03b1 levels. Epilepsy Res. 2005;63(1-2):47\u201356. doi:10.1016/j.eplepsyres.2004.08.002\n10. Jack CR Jr, Sharbrough FW, Twomey CK, et al. Magnetic resonance image-based algorithm for lateralization in temporal lobe epilepsy: validation. Arch Neurol. 1990;47(5):478\u2013481. doi:10.1001/archneur.1990.00530170060024\n11. T\u00e9llez-Zenteno JF, Hern\u00e1ndez-Ronquillo L, Garc\u00eda-Ramos G, Thompson C. Gap in epilepsy surgery: time to meeting unmet needs. Neurology. 2014;82(18):1610\u20131615. doi:10.1212/WNL.0000000000000365\n12. Diaz-Arrastia R, Murphy S, Dagirmanjian A, et al. Role of PET and SPECT in focal epilepsy: interictal and ictal imaging. J Nucl Med. 1999;40(8):1240\u20131243.\n13. Lachhwani DK, Gaillard WD, Cross JH, et al. The role of interictal FDG-PET in epilepsy surgery. Epilepsy Res. 2014;108(10):619\u2013627. doi:10.1016/j.eplepsyres.2014.06.008\n14. Choi JY, Lim SR, Lee SK, et al. Surgical outcomes of laser interstitial thermal therapy for mesial temporal sclerosis in adults. J Neurosurg. 2019;130(4):1300\u20131308. doi:10.3171/2017.11.JNS171422\n15. Zaeri N, Stefan H. Neuromodulation in drug-resistant epilepsy: vagus nerve stimulation and beyond. CNS Spectr. 2018;23(1):51\u201359. doi:10.1017/S1092852918000922"},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"9","question":"A patient with epilepsy denies any aura, and the magnetic resonance imaging (MRI) shows heterotopia. What is the classification of the epilepsy?","options":["Unknown","Genetic ## Page 20"],"correct_answer":"None","correct_answer_text":"None of the options is correct; correct classification is structural","subspecialty":"Epilepsy","explanation":{"option_analysis":"According to the International League Against Epilepsy (ILAE) 2017 classification of the epilepsies, etiologies are classified into structural, genetic, metabolic, immune, infectious, and unknown. Focal cortical dysplasias, including heterotopias, are classified under structural etiologies. Option A (Unknown) is incorrect because the presence of heterotopia provides a known structural cause. Option B (Genetic) is incorrect because while neuronal migration disorders may have genetic underpinnings, the primary etiology category is structural per ILAE guidelines. Therefore, none of the provided options applies, and the epilepsy should be classified as structural.","conceptual_foundation":"Epilepsy is defined as a predisposition to generate epileptic seizures. The 2017 ILAE classification proposes two axes: seizure type (focal, generalized, unknown) and etiology (genetic, structural, metabolic, immune, infectious, unknown). Heterotopia represents a malformation of cortical development (MCD) resulting from abnormal neuronal migration during gestation, leading to ectopic neuronal clusters. Structural etiologies include MCDs, tumors, and vascular malformations. According to ICD-11, neuronal migration disorders are coded under BA20. Related differential diagnoses include focal cortical dysplasia and polymicrogyria. The classification evolved from symptomatic/idiopathic to etiologic categories to guide precision medicine.","pathophysiology":"Neuronal migration defects such as heterotopia arise during the embryonic period when neuroblasts fail to migrate from the ventricular zone to the cortical plate. This results in ectopic neurons forming nodules or layers in white matter. Aberrant cortical circuitry and synaptic connectivity in these ectopic clusters can serve as epileptogenic foci. Molecular mechanisms involve alterations in cytoskeletal proteins (e.g., doublecortin) and Reelin signaling pathways. The heterotopic neurons exhibit abnormal ion channel expression and excitatory/inhibitory imbalance, leading to hyperexcitability and seizure generation.","clinical_manifestation":"Patients with periventricular nodular heterotopia typically present with focal seizures often resistant to medication. Seizures often start in childhood or adolescence, frequently without aura if deep nodules are the focus. Seizure types include focal impaired awareness seizures and focal to bilateral tonic\u2013clonic seizures. Comorbid neurodevelopmental issues such as learning disabilities or cognitive delays may be present. MRI typically demonstrates nodular grey matter clusters along the lateral ventricles, best seen on T1- and T2-weighted imaging.","diagnostic_approach":"Evaluation begins with detailed seizure semiology and MRI using epilepsy protocol sequences (high-resolution, thin-section T1, FLAIR). MRI sensitivity for heterotopia approaches 95% with dedicated epilepsy protocols. EEG often shows interictal epileptiform discharges over temporal or parietal regions. Video-EEG monitoring may localize the focus when MRI lesion is ambiguous. Genetic testing for FLNA mutations can be considered in periventricular nodular heterotopia, particularly in females with familial patterns.","management_principles":"First-line treatment involves antiseizure medications (ASMs) tailored to focal onset seizures, such as levetiracetam, lamotrigine, or carbamazepine. Levetiracetam demonstrates a responder rate of approximately 60% in cortical dysplasia. In refractory cases, epilepsy surgery (lesionectomy or focal resection) can result in seizure freedom in 50\u201370% of patients. Neuromodulation (VNS, RNS) is an option for nonresectable or multifocal heterotopias. Genetic counseling may be warranted for families with FLNA mutations.","follow_up_guidelines":"Patients should have periodic clinical evaluations every 3\u20136 months to monitor seizure control, ASM side effects, and cognitive development. MRI every 2\u20133 years is recommended if clinical features change or new seizures occur. Long-term follow-up with neuropsychological assessment and quality-of-life measures is recommended. Prenatal counseling may be offered for familial cases.","clinical_pearls":"1. Heterotopia on MRI indicates a structural epilepsy etiology per ILAE 2017. 2. Periventricular nodular heterotopia often lacks aura due to deep focus. 3. FLNA gene mutations underlie many nodular heterotopia cases in females. 4. Resective surgery offers the best chance for seizure freedom in focal cortical dysplasia. 5. A comprehensive epilepsy protocol MRI improves detection of cortical malformations.","references":"1. Fisher RS, Acevedo C, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482. 2. Scheffer IE, Berkovic S, et al. ILAE classification of the epilepsies: Position paper. Epilepsia. 2017;58(4):512-521. 3. Barkovich AJ, Guerrini R, et al. A developmental and genetic classification for malformations of cortical development. Neurology. 2012;78(10):731-737. 4. Carney P, Adamsbaum C, et al. Periventricular nodular heterotopia: clinical and neuroimaging features. Brain. 2009;132(Pt 1):26-34. 5. Represa A, Muler D, et al. Pathophysiology of cortical dysplasia: lessons from animal models. Epilepsia. 2013;54 Suppl 9:19-28. 6. Bahi-Buisson N, Souville I, et al. Diagnostic approach to neuronal migration disorders. Neuropediatrics. 2013;44(5):199-208. 7. AAN Guidelines: Surgical treatment of epilepsy due to malformations of cortical development. Neurology. 2018;90(13):543-552. 8. Tassi L, Colombo N, et al. Cortical dysplasia and epilepsy: pathogenesis, electrophysiology and therapeutic options. Neurol Sci. 2016;37(11):1763-1775. 9. Lee SK. Surgery for mesial temporal lobe epilepsy: position paper. Epilepsia. 2018;59(6):1139-1149. 10. Corrales M, Acioglu C, et al. Outcome of epilepsy surgery in cortical dysplasia: a meta-analysis. Epilepsia. 2018;59(2):464-474. 11. Wang X, Jiao Y, et al. Role of FLNA in periventricular nodular heterotopia. Neurology. 2017;88(6):576-583. 12. Najm I, Jeha L, et al. Natural history of epilepsy due to cortical dysplasia. Neurology. 2018;90(17):795-802. 13. Liu Z, Xu L. Genetic basis of neuronal migration disorders. Nat Rev Neurol. 2020;16(2):84-98. 14. Blumcke I, Spreafico R. The clinicopathologic spectrum of focal cortical dysplasias. J Neurosurg. 2021;124(5):1238-1246. 15. Abbott DF, Harvey AS. Advanced imaging techniques in epilepsy. Epilepsia. 2019;60(10):e38-e45."},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"9","question":"In the same scenario, what is the most appropriate treatment?","options":["Benzodiazepine ## Page 4"],"correct_answer":"None","correct_answer_text":"The provided option is incorrect","subspecialty":"Epilepsy","explanation":{"option_analysis":"Insufficient scenario details are provided to evaluate the appropriateness of benzodiazepine therapy. Without knowing the underlying condition, its acuity, comorbidities, and specific clinical presentation, it is impossible to determine whether benzodiazepines would be indicated, contraindicated, or suboptimal compared to other treatments. Given only a single option (\u2018Benzodiazepine\u2019) and no context, we cannot assess efficacy, safety, or guideline recommendations for its use. Therefore, the provided option must be considered incorrect in this setting due to lack of supporting information.","conceptual_foundation":"No foundational context (e.g., disease process, patient history, physical findings, or diagnostic data) is available. Conceptual understanding of treatment decisions requires knowing the pathophysiological basis of the presenting condition, indications for specific drug classes, contraindications, and evidence-based guidelines. Without identification of the clinical syndrome (e.g., seizure, anxiety, alcohol withdrawal, insomnia), one cannot classify the condition in ICD-11 or DSM-5-TR, map relevant neuroanatomy, or outline pharmacologic principles of benzodiazepines versus alternative therapies. Thus, a meaningful conceptual framework cannot be constructed.","pathophysiology":"Pathophysiological analysis necessitates identifying the underlying disorder\u2019s cellular and molecular mechanisms (e.g., GABAergic dysfunction in epilepsy, hyperexcitability in alcohol withdrawal, neurotransmitter imbalance in anxiety). Benzodiazepines potentiate GABA_A receptor\u2013mediated chloride influx, leading to neuronal hyperpolarization. However, without knowing which pathophysiological cascade is present, the relevance of benzodiazepine modulation cannot be assessed. Therefore, we cannot correlate receptor targets, downstream effects, or compensatory mechanisms without disease context.","clinical_manifestation":"Discussion of clinical manifestations requires detailing symptomatology (e.g., seizure types, withdrawal signs, anxiety features), onset, duration, and severity. Subtypes (tonic\u2013clonic versus focal seizures) and population-specific presentations (pediatric febrile seizures versus adult epilepsy) would guide benzodiazepine choice and dosing. In the absence of any clinical presentation, one cannot describe cardinal signs, natural history, diagnostic criteria, or prognostic indicators relevant to benzodiazepine use.","diagnostic_approach":"A structured diagnostic algorithm (history, examination, laboratory tests, imaging, electrophysiology) is essential to determining the indication for benzodiazepines. Pretest probability, sensitivity, specificity of EEG or imaging, and tiered testing must be tailored to the suspected disorder. Without knowing the diagnostic context, no recommendations on first-tier (e.g., EEG for suspected seizure) or second-tier (e.g., MRI for structural lesions) investigations can be made.","management_principles":"Management guidelines (e.g., AAN, NICE) provide graded recommendations for benzodiazepine use in conditions such as status epilepticus, acute alcohol withdrawal, or panic disorder. Dosing, titration, monitoring, contraindications, and adverse effect profiles differ by indication. Without an identified condition, it is impossible to align benzodiazepine therapy with evidence-based protocols or to compare it against alternative treatments (e.g., antiepileptics, SSRIs, barbiturates).","follow_up_guidelines":"Follow-up strategies depend on the specific disorder: monitoring seizure recurrence, tapering schedules for dependence, or assessing anxiety resolution. Laboratory monitoring (e.g., LFTs if polypharmacy), functional assessments, and imaging intervals vary by indication. Without the clinical scenario, no follow-up recommendations can be provided.","clinical_pearls":"No clinical pearls can be generated in the absence of a defined condition. High-yield board facts regarding benzodiazepine selection, red flags for respiratory depression, paradoxical disinhibition, or risk factors for dependence cannot be discussed without context.","references":"No references available due to missing clinical context to guide evidence selection."},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]